Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3" by M. P. Goetz et al.

Subjects

Subjects :

Humans
Female
Receptors, Estrogen metabolism
Receptors, Progesterone metabolism
Aminopyridines
Benzimidazoles
Breast Neoplasms drug therapy
Breast Neoplasms mortality
Breast Neoplasms pathology
Aromatase Inhibitors therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Receptor, ErbB-2 metabolism
Receptor, ErbB-2 antagonists & inhibitors

Details

Language :

English

ISSN :

1569-8041

Volume :

35

Issue :

8

Database :

MEDLINE

Journal :

Annals of oncology : official journal of the European Society for Medical Oncology

Publication Type :

Editorial & Opinion

Accession number :

38838846

Full Text :

https://doi.org/10.1016/j.annonc.2024.05.543